NCT05644561 2026-04-17Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc.Phase 3 Active not recruiting12 enrolled